---
document_datetime: 2023-09-21 19:50:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ervebo-epar-all-authorised-presentations_en.pdf
document_name: ervebo-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7153223
conversion_datetime: 2025-12-18 22:37:34.971796
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/19/1392/001 | Ervebo            | --¹        | Solution for injection | Intramuscular use         | vial (glass)          | 1 ml                      | 10 vials    |

--¹ One dose (1 mL) contains:

Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP¹² live, attenuated) ≥72 million pfu³ ¹Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP) ²Produced in Vero cells ³pfu= plaque-forming units